CL2019000274A1 - Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat). - Google Patents
Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat).Info
- Publication number
- CL2019000274A1 CL2019000274A1 CL2019000274A CL2019000274A CL2019000274A1 CL 2019000274 A1 CL2019000274 A1 CL 2019000274A1 CL 2019000274 A CL2019000274 A CL 2019000274A CL 2019000274 A CL2019000274 A CL 2019000274A CL 2019000274 A1 CL2019000274 A1 CL 2019000274A1
- Authority
- CL
- Chile
- Prior art keywords
- ghrelin
- acyltransferase
- goat
- inhibitors
- oxadiazolopyridine derivatives
- Prior art date
Links
- 241000283707 Capra Species 0.000 title 1
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title 1
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical class C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A LOS COMPUESTOS DE LA FÓRMULA GENERAL I, EN DONDE LOS GRUPOS R1 , R2 Y N SE DEFINEN DE ACUERDO CON LA REIVINDICACIÓN 1, QUE TIENEN PROPIEDADES FARMACOLÓGICAS VALIOSAS, EN PARTICULAR, SE FIJAN A GHRELIN O-ACIL TRANSFERASA (GOAT) Y MODULAN SU ACTIVIDAD. LOS COMPUESTOS SON ADECUADOS PARA EL TRATAMIENTO Y LA PREVENCIÓN DE ENFERMEDADES QUE SE PUEDEN VER INFLUENCIADAS POR ESTE RECEPTOR, TALES COMO ENFERMEDADES METABÓLICAS, EN PARTICULAR, OBESIDAD.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16183047 | 2016-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000274A1 true CL2019000274A1 (es) | 2019-05-03 |
Family
ID=56609762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000274A CL2019000274A1 (es) | 2016-08-05 | 2019-02-01 | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat). |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9994591B2 (es) |
| EP (1) | EP3494120B1 (es) |
| JP (1) | JP6651054B2 (es) |
| KR (1) | KR102496075B1 (es) |
| CN (1) | CN109843891B (es) |
| AR (1) | AR109296A1 (es) |
| AU (1) | AU2017307033B2 (es) |
| CL (1) | CL2019000274A1 (es) |
| CO (1) | CO2019000601A2 (es) |
| CY (1) | CY1124381T1 (es) |
| DK (1) | DK3494120T3 (es) |
| EA (1) | EA037277B1 (es) |
| ES (1) | ES2874587T3 (es) |
| HR (1) | HRP20210908T1 (es) |
| HU (1) | HUE054928T2 (es) |
| IL (1) | IL264506B (es) |
| LT (1) | LT3494120T (es) |
| MA (1) | MA45843B1 (es) |
| MX (1) | MX384847B (es) |
| MY (1) | MY197064A (es) |
| PE (1) | PE20190414A1 (es) |
| PH (1) | PH12019500254A1 (es) |
| PL (1) | PL3494120T3 (es) |
| PT (1) | PT3494120T (es) |
| RS (1) | RS61937B1 (es) |
| SA (1) | SA519401039B1 (es) |
| SG (1) | SG11201811804QA (es) |
| SI (1) | SI3494120T1 (es) |
| TW (1) | TWI749042B (es) |
| UA (1) | UA124267C2 (es) |
| WO (1) | WO2018024653A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11136337B2 (en) | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| EA202091804A1 (ru) * | 2018-02-02 | 2020-12-24 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) |
| WO2019149657A1 (en) * | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| EA202091803A1 (ru) | 2018-02-02 | 2020-12-16 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| CN115916789B (zh) * | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| HUE066997T2 (hu) | 2020-05-22 | 2024-09-28 | Boehringer Ingelheim Int | Eljárás alkil-7-amino-5-metil-[1,2,5]oxidiazol[3,4-B]piridin-karboxilát elõállítására |
| CN112014340A (zh) * | 2020-09-01 | 2020-12-01 | 广西玮美生物科技有限公司 | 非人灵长类动物胃饥饿素的检测方法 |
| CN118652261B (zh) * | 2024-05-29 | 2025-02-07 | 南京理工大学 | 一种耐热荧光活性含能化合物及其合成方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| CL2007003580A1 (es) | 2006-12-11 | 2009-03-27 | Boehringer Ingelheim Int | Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes. |
| GEP20135944B (en) | 2007-02-15 | 2013-10-25 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| WO2010070251A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070253A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070255A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| CN104961822A (zh) | 2009-07-13 | 2015-10-07 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
| BR112014015681A2 (pt) | 2011-12-23 | 2019-09-24 | Boehringer Ingelheim Int | análogos de glucagon |
| JP6106179B2 (ja) * | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | 芳香環化合物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (en) * | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| EA202091804A1 (ru) | 2018-02-02 | 2020-12-24 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) |
| EA202091803A1 (ru) | 2018-02-02 | 2020-12-16 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) |
| WO2019149657A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| US11136337B2 (en) * | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
-
2017
- 2017-07-31 LT LTEP17743064.2T patent/LT3494120T/lt unknown
- 2017-07-31 MX MX2019001427A patent/MX384847B/es unknown
- 2017-07-31 CN CN201780047100.1A patent/CN109843891B/zh active Active
- 2017-07-31 DK DK17743064.2T patent/DK3494120T3/da active
- 2017-07-31 PL PL17743064T patent/PL3494120T3/pl unknown
- 2017-07-31 JP JP2019506164A patent/JP6651054B2/ja active Active
- 2017-07-31 PE PE2019000271A patent/PE20190414A1/es unknown
- 2017-07-31 UA UAA201901840A patent/UA124267C2/uk unknown
- 2017-07-31 RS RS20210702A patent/RS61937B1/sr unknown
- 2017-07-31 AU AU2017307033A patent/AU2017307033B2/en active Active
- 2017-07-31 KR KR1020197006448A patent/KR102496075B1/ko active Active
- 2017-07-31 MY MYPI2018002719A patent/MY197064A/en unknown
- 2017-07-31 US US15/664,119 patent/US9994591B2/en active Active
- 2017-07-31 EP EP17743064.2A patent/EP3494120B1/en active Active
- 2017-07-31 SG SG11201811804QA patent/SG11201811804QA/en unknown
- 2017-07-31 MA MA45843A patent/MA45843B1/fr unknown
- 2017-07-31 EA EA201990418A patent/EA037277B1/ru not_active IP Right Cessation
- 2017-07-31 SI SI201730770T patent/SI3494120T1/sl unknown
- 2017-07-31 ES ES17743064T patent/ES2874587T3/es active Active
- 2017-07-31 WO PCT/EP2017/069274 patent/WO2018024653A1/en not_active Ceased
- 2017-07-31 HR HRP20210908TT patent/HRP20210908T1/hr unknown
- 2017-07-31 HU HUE17743064A patent/HUE054928T2/hu unknown
- 2017-07-31 PT PT177430642T patent/PT3494120T/pt unknown
- 2017-08-04 TW TW106126319A patent/TWI749042B/zh active
- 2017-08-04 AR ARP170102213A patent/AR109296A1/es active IP Right Grant
-
2018
- 2018-05-09 US US15/974,882 patent/US10308667B2/en not_active Ceased
-
2019
- 2019-01-22 CO CONC2019/0000601A patent/CO2019000601A2/es unknown
- 2019-01-28 IL IL264506A patent/IL264506B/en active IP Right Grant
- 2019-02-01 CL CL2019000274A patent/CL2019000274A1/es unknown
- 2019-02-05 SA SA519401039A patent/SA519401039B1/ar unknown
- 2019-02-06 PH PH12019500254A patent/PH12019500254A1/en unknown
-
2020
- 2020-10-14 US US17/069,940 patent/USRE49446E1/en active Active
-
2021
- 2021-06-14 CY CY20211100525T patent/CY1124381T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000274A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat). | |
| CL2020001909A1 (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). | |
| ECSP20050785A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CL2019000588A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tlr. | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
| UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| MX2020004504A (es) | Derivados de fenoximetilo. | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| ECSP20050791A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| MX2016010675A (es) | Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa). | |
| MX2016015062A (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina los cuales son inhibidores de janus cinasas (jak). | |
| CU24482B1 (es) | Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
| DOP2017000289A (es) | Moduladores de receptor nuclear | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| MX385658B (es) | Inhibidores del receptor de glucocorticoides. | |
| DOP2016000211A (es) | Pirazinas moduladoras de gpr6 | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. |